AB Science (OTCMKTS:ABSCF – Get Free Report) is expected to announce its results after the market closes on Friday, September 25th. Analysts expect the company to announce earnings of ($0.0799) per share and revenue of $0.6850 million for the quarter.
AB Science Price Performance
AB Science stock opened at $1.12 on Thursday. AB Science has a 52 week low of $1.12 and a 52 week high of $1.37. The stock has a fifty day moving average of $1.12 and a 200-day moving average of $1.20.
About AB Science
AB Science is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the discovery and development of protein kinase inhibitors. Its core focus is on the design of orally administered small-molecule therapies that target key signaling pathways involved in oncology, inflammatory disorders and neurodegenerative diseases. The company’s lead asset, masitinib, is a selective tyrosine kinase inhibitor that has been evaluated in multiple Phase 2 and Phase 3 clinical trials, including studies in mastocytosis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and severe asthma.
Since its founding in 2001 by Dr.
Further Reading
- Five stocks we like better than AB Science
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for AB Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AB Science and related companies with MarketBeat.com's FREE daily email newsletter.
